The first biosimilar to Amgen’s Nesp/Aranesp (darbepoetin alfa) is set to reach the Persian Gulf following an agreement between biosimilar manufacturer Chong Kun Dang Pharmaceutical and Oman-based Menagen Pharmaceutical Industries.
The Korean firm and Menagen have established a strategic partnership for the Gulf Cooperation Council region – which comprises Oman,...






